Market Trends of 3D Cardiac Mapping Systems Industry
The Electroanatomical Mapping Segment is Expected to Hold Significant Market Share During the Forecast Period
Electroanatomical mapping systems use mapping catheters to estimate the electrical activity of cardiac muscle and create comprehensive three-dimensional electroanatomic maps of patients' hearts. The clinical advantages of the electroanatomical mapping system and increasing technological advancements are expected to drive the segment's growth during the forecast period.
The clinical advantages of the electroanatomical mapping systems, including enhanced diagnostic accuracy, improved treatment outcomes, minimized procedure time, and others, are expected to fuel the demand for these systems during the forecast period. For instance, according to an article published in the Indian Pacing Electrophysiol Journal in February 2022, the electroanatomical mapping technology has been reported to decrease fluoroscopic exposure and radiation dose, with less significant effects on procedural duration time and success rates.
In addition, according to the same source mentioned above, several electroanatomical mapping (EAM) systems have advanced features, such as improved ability to map non-sustained or hemodynamically unstable arrhythmias, ability to display diagnostic and mapping catheter positions, and wide compatibility with a variety of catheters. Hence, such clinical advantages of the EAM technological systems are anticipated to drive the growth of this segment in the coming years.
Also, the increasing technological advancements in EAM technologies are expected to drive the segment growth during the forecast period. For instance, according to an article published in HeartRhythm Case Reports in October 2023, the use of an electroanatomic mapping system with high-density multipolar mapping catheters to guide transvenous atrial pacing lead implantation in a Fontan patient is increasing, which ultimately raises the demand for the electroananatomical 3D mapping devices. Hence, this factor is likely to propel the growth of the segment during the forecast period.
Hence, clinical advantages of the electroanatomic mapping system and increasing technological advancements are expected to drive the segment growth during the forecast period.
North America is Expected to Hold the Significant Market Share During the Forecast Period
The geographical analysis of the 3D cardiac mapping system market shows that North America holds a significant market share in the global market. This is due to the rising prevalence of various cardiovascular diseases in the region, the presence of prominent players, and the increasing number of product launches.
The growing burden of cardiovascular diseases in North America is expected to drive market growth during the forecast period. For instance, as per the report published by Scripps Health in January 2022, approximately one in 18 people, or 5% of the United States population, had an arrhythmia in 2022. It also highlighted that one in four adult Americans over the age of 40 have a possibility of developing an irregular heartbeat. Hence, the high prevalence of cardiovascular diseases is anticipated to augment the growth of the market in the coming years.
Also, increasing strategic activities such as product launches and acquisitions are expected to drive the market during the forecast period. For instance, in August 2022, Medtronic, a medical device company, acquired Affera Inc., a medical technology that provides cardiac arrhythmia treatment devices. This acquisition expanded the company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform encompassing a differentiated, fully integrated diagnostic, focal pulsed field, and radiofrequency ablation solution. Hence, such product launches are also likely to drive the growth of the market during the forecast period.
Thus, North America is expected to witness significant growth during the forecast period due to the above-mentioned factors, such as the rising prevalence of cardiovascular diseases and increasing strategic activities such as product launches.
